WILMINGTON, Delaware-AstraZeneca’s nonsteroidal aromatase inhibitor Arimidex (anastrozole) has received FDA approval for the adjuvant treatment of hormone-receptor-positive early-stage breast cancer in postmenopausal women. The agent was previously approved as first-line treatment of hormone-receptor-positive advanced breast cancer in postmenopausal women and as second-line treatment for those whose disease has progressed following treatment with tamoxifen (Nolvadex).
The results of a phase III trial of capecitabine (Xeloda) in combination with docetaxel (Taxotere) for the treatment of metastatic breast cancer were published in a recent issue of the Journal of Clinical Oncology (20:2812-2823, 2002). Based on
The results of two clinical trials evaluating fulvestrant (Faslodex) for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy were published in a recent issue of the Journal
ORLANDO-An open-label randomized study comparing letrozole (Femara) and anastrozole (Arimidex), the two US FDA-approved nonsteroidal aromatase inhibitors, found a higher overall response rate for letrozole as second-line therapy in women with metastatic breast cancer.
United States seems to have a predilection for declaring "war" on its internal problems, be they poverty, drugs, or cancer. In the latter part of the past century particularly, military metaphors became part of the vocabulary used by Americans to
In an international study of the two leading aromatase inhibitors, data demonstrate that 50% more women with advanced breast cancer respond to letrozole (Femara) than to anastrozole (Arimidex); ie, more women treated with letrozole achieved at
ROCKVILLE, Maryland-The Food and Drug Administration has approved the inclusion of the PathVysion HER-2 DNA Probe Kit, a new genedetection test, in the labeling of Herceptin (trastuzumab, Genentech). PathVysion is made and marketed by Vysis, Inc., a subsidiary of Abbott Laboratories. It joins HercepTest (DAKO) as the second screening test listed in the Herceptin labeling.
ORLANDO-Compared with the aromatase inhibitor anastrozole (Arimi-dex), mean duration of response is significantly greater with fulvestrant (Faslo-dex) in postmenopausal women with advanced breast cancer who have progressed on prior endocrine therapy. For other key endpoints, fulvestrant was at least as effective as anastrozole, according to a poster presentation at the 38th Annual Meeting of the American Society of Clinical Oncology (abstract 160).
Received approval from the US Food and Drug Administration (FDA) to include information about Abbott’s PathVysion-a fluorescence in situ hybridization (FISH) test-in the product insert for trastuzumab (Herceptin). FISH is used to detect human
With the advent of methods for determining genetic susceptibility to breast cancer, there is a growing focus on prevention as a primary strategy. In this context, more women will receive information about the role of prophylactic mastectomy as a definitive management strategy. Drs. Ghosh and Hartmann have provided a thorough review of the salient issues in prophylactic mastectomy. Their discussion of the procedure and its history set the stage for further discussion of the relative efficacy of prophylactic mastectomy in reducing the risk of breast cancer in women.
Ghosh and Hartmann present an excellent overview on the risk reduction that prophylactic mastectomy offers the high-risk patient. Dr. Hartmann and the Mayo Clinic remain leaders in this field. As cited in their recent series, the risk of developing breast cancer is reduced 89.5% to 100% in high-risk women who choose to undergo prophylactic mastectomy.[1] In the same year, Meijers-Heijboer et al supported these findings, documenting a 100% relative risk reduction.[2] The fact that prophylactic surgery offers a dramatic reduction in the risk of breast cancer to high-risk patients appears unquestionable.
The emerging era of targeted cancer therapies has focused laboratory scientists and clinicians on the need to define and understand molecular targets of novel drugs. For breast cancer patients and doctors, this trend is not news-efforts have been under way for decades to identify the estrogen and progesterone receptors and define the value of these markers as predictors of response to hormonal therapy.
The need for accurate detection of HER2 status is becoming more apparent, as therapeutic decisions are influenced by this information in both the adjuvant and advanced-stage setting. Since the US Food and Drug
The management of women at high risk for breast cancer presents a clinical dilemma to the health-care provider as well as to the woman herself. Current options include surveillance, prophylactic surgery (mastectomy and/or
The emerging era of targeted cancer therapies has focused laboratory scientists and clinicians on the need to define and understand molecular targets of novel drugs. For breast cancer patients and doctors, this trend is not news-efforts have been under way for decades to identify the estrogen and progesterone receptors and define the value of these markers as predictors of response to hormonal therapy.
WASHINGTON-A new technique employing high-resolution contrast-enhanced magnetic resonance imaging (MRI) can distinguish between benign and malignant breast lesions by showing lesion perfusion patterns (images and Figure 1). Hadassa Degani, PhD, head of the Department of Biological Regulation, the Weizmann Institute of Science, Rehovot, Israel, discussed the method, developed in her lab, at the Susan G. Komen Breast Cancer Foundation 5th Annual Conference on Innovations in Quality Care.
BETHESDA, Maryland-Results from the largest epidemiologic investigation of possible links between two major types of environmental pollutants and breast cancer indicate a 50% increase in risk of the disease for women exposed to polycyclic aromatic hydrocarbons (PAHs) at the highest level. However, researchers failed to find an association between organochlorine compounds, which include DDT, and an increased risk of breast cancer.
BETHESDA, Maryland-Results from the largest epidemiologic investigation of possible links between two major types of environmental pollutants and breast cancer indicate a 50% increase in risk of the disease for women exposed to polycyclic aromatic hydrocarbons (PAHs) at the highest level. However, researchers failed to find an association between organochlorine compounds, which include DDT, and an increased risk of breast cancer.
SAN FRANCISCO-Women who gain 38 lb or more during pregnancy have a 40% greater risk of postmenopausal breast cancer than women who gain less weight, Leena Hilakivi-Clarke, PhD, said at the 93rd Annual Meeting of the American Association for Cancer Research (abstract 1169).
ORLANDO-SGN-15 (a monoclonal antibody conjugated to doxorubicin) plus docetaxel (Taxotere) was well tolerated in patients with metastatic breast cancer or colorectal cancer and showed objective responses, according to a phase II trial.
ORLANDO-Early prophylactic mastectomy benefits women at high risk of hereditary breast cancer, according to a presentation at the 38th Annual Meeting of the American Society of Clinical Oncology (abstract 1694). The study revealed the presence of high-risk premalignant lesions in the removed breast tissue of more than half of the women undergoing the procedure.
SAN FRANCISCO-A new monoclonal antibody, TRA-8, produces a higher rate of regression in breast cancer when used with paclitaxel (Taxol) or doxorubicin (Adriamycin) than either of the chemotherapies alone, according to animal studies
ATLANTA-Compared with independent double reading of mammograms, consensus double reading detects slightly more cancers while significantly decreasing recall rates, thereby minimizing the anxiety that women might experience from undergoing a second mammogram, Susan Harvey, MD, said at the 102nd Annual Meeting of the American Roentgen Ray Society (abstract 63).
WASHINGTON-About 30% of breast cancer patients show overexpression of the HER-2/neu oncogene, and trastuzumab (Herceptin), a monoclonal antibody targeting HER-2, has been shown to block the gene’s receptor activity. But because the response rate to trastuzumab "is not ideal," there is "still a need for a better therapeutic agent" aimed at HER-2, said Mong-Hong Lee, PhD, assistant professor of molecular and cellular oncology, M.D. Anderson Cancer Center.
ORLANDO-A large review of patients treated at M.D. Anderson Cancer Center suggests that survival after a first breast cancer recurrence has greatly improved over time in patients diagnosed in the last 25 years. The investigators believe that new therapies, above and beyond the anthracyclines, may be affecting survival rates.
